IASLC Resources for JLCS Annual Meeting

The IASLC proudly celebrates our Association's rich and vibrant history, intertwined with our Japanese members' invaluable contributions and dedicated participation. Over the years, our organization has cultivated deep-rooted connections with experts from Japan, fostering a spirit of collaboration and cultural exchange. This engagement has played an integral role in shaping our collective journey, and we are excited to share the remarkable resources of this enduring partnership with you and explore the shared experiences and achievements that have defined our unique Association.

Engagement Opportunities With IASLC

Become an IASLC Member

Start Here

Submit Your Research to JTO or JTO CRR

Learn More

Attend an IASLC Meeting

View Upcoming Meetings

close-up-scientist-using-microscope-laboratory-room-while-making-medical-testing-research.jpg

Apply for a Research Grant

Learn More

Become A Journal Manuscript Reviewer

Learn More

Participate in an IASLC Podcast

Learn More

Encourage a Colleague to Join the IASLC

Learn More

Participate in an IASLC Webinar

Learn More

*New Committee Nominations Will Take Place in 2025*

Volunteer for an IASLC Committee

Learn More

IASLC Membership Is Open To Any

Physician

Scientist

Nurse

Patient/Survivor & Caregiver

Pharmacist

Industry Member

Allied Health Professional

Others Interested in Thoracic Cancers

Become an IASLC Member!

In recognition of the partnership JLCS has with the IASLC, we are excited to offer a special join rate during this meeting for a $75 1-Year Regular Membership or a $25 1-Year Allied Health Professional membership! Or, opt for a three-year membership starting at $375 for regular members and $75 for Allied Health Professionals! Scan here to sign up to receive the discount code.
For first-time members only.

For questions regarding membership at the IASLC, please email membership@iaslc.org

Join the IASLC Today!

Renew My IASLC Membership

Access Japanese-Language Resources

Resources

免疫組織化学診断 IASLCアトラス編集者 Yasushi Yatabe, MD, PhD Alain C. Borczuk, MD Wendy A. Cooper, MBBS, BSC(Med), FRCPA, PhD Sanja Dacic, MD, PhD Keith M. Kerr, MD, FRCPATH, FRCPE Andre L. Moreira, MD, PhD Ming Sound Tsao, MD, FRCPC

Japanese Resource

Practice Resource

免疫組織化学診断 IASLCアトラス

Download (20.2 MB)

General

Japanese Resource

Patient Resource

Practice Resource

Publication

IASLC Language Guide

The following Language Guide has been developed by members of the IASLC to provide guidelines on...

Download (457.24 KB)

Lung Cancer Considered Podcasts

LCC in Japanese: State of the Art for EGFR

This episode of Lung Cancer Considered is recorded entirely in Japanese and focuses on EGFR-mutated lung cancer.

Listen Now

WCLC 2023 Recap

Lung Cancer Considered hosts Dr. Narjust Florez & Dr. Stephen Liu recap #WCLC23, discussing the meeting's most impactful research, including data presented on the MARS2, FLAURA2...

Listen Now

LCC in Japanese: Treating Lung Cancer in Japan

In keeping with its mission to cover lung cancer from a global perspective, this episode of Lung Cancer Considered focuses on lung cancer in Japan. Host Dr. Misako Nagasaka, a...

Listen Now

RESEARCH GRANT PROGRAM

Through partnering with the IASLC Foundation, other foundations, nonprofits, corporations, and individual donors, the IASLC provides funding opportunities each year to facilitate research advances and save lives.

Learn More

Highly-Cited JTO Articles

159P Optimization and validation of a circulating microRNA biomarker panel for early detection of lung cancer in a Japanese population

Screening for lung cancer using imaging modalities such as low-dose CT (LDCT) is currently recommended only for high-risk populations. However, the proportion of lung cancer in...

Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)

The PACIFIC regimen of consolidation therapy with the programmed cell death-ligand 1 inhibitor durvalumab after definitive concurrent chemoradiation therapy has become a standard...

Lung Cancer in Japan

Japan is located in East Asia and consists of five large islands and numerous smaller islands, with a total of 6852 islands (Fig. 1). Mountainous areas cover 75% of the country...

Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan

Patients with cancer have been prioritized for vaccination against severe acute respiratory syndrome coronavirus 2. Nevertheless, there are limited data regarding the safety...

EP08.02-115 A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan

Three years have passed since lorlatinib was approved in Japan in September 2018 for the treatment of ALK+ NSCLC. As not much is known about lorlatinib efficacy when given after...

Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L

About 10% of patients with locally advanced NSCLC (LA-NSCLC) harbor EGFR mutation and recent reports suggested the declined benefit with an immune checkpoint inhibitor in this...

Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M–positive NSCLC Treated With Osimertinib in Japan

Using real-world Japanese postmarketing data, we characterized interstitial lung disease (ILD) development during the second- or later-line osimertinib treatment for EGFR mutation...

PDF [402 KB] Figures Save Share Reprints Request Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial

This phase 2 trial evaluated the efficacy and safety of brigatinib in patients with advanced ALK-positive NSCLC refractory to alectinib or other ALK tyrosine kinase inhibitors...

Upcoming IASLC Meetings

2024 Targeted Therapies of Lung Cancer Meeting

The IASLC Targeted Therapies of Lung Cancer Meeting is a dynamic meeting with a long tradition of summarizing data on relevant targets for new therapies and sharing data on...

Learn More

2024 European Lung Cancer Congress

ELCC 2024 is taking place in Prague, Czech Republic, from 20-23 March 2024. ELCC 2024 is a collaborative effort of important multidisciplinary societies working together to advance...

Learn More

2024 World Conference on Lung Cancer

Join us for the IASLC 2024 World Conference on Lung Cancer in San Diego, California from September 7-10, 2024. The WCLC has played an integral part in facilitating progress by...

Learn More

2024 Asia Conference on Lung Cancer

The IASLC 2024 Asia Conference on Lung Cancer will take place October 17-19, 2024 in Hong Kong. ACLC will explore the latest developments in clinical & basic research, clinical...

Watch the Press Briefing

IASLC Members receive discounted registration for our meetings. Complimentary registration is available for survivors, caregivers, and advocates.

Highly-Cited JTO CRR Articles

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN

Lorlatinib, a third-generation ALK inhibitor, was found to have improved efficacy versus crizotinib in patients with previously untreated, advanced ALK-positive NSCLC in the...

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan

Lorlatinib is an ALK tyrosine kinase inhibitor approved in Japan for the treatment of advanced ALK+ NSCLC. There has been little evidence about lorlatinib efficacy after first-line...

Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)

The efficacy and safety of atezolizumab in previously treated patients with NSCLC have been established in the registrational phase 3 OAK trial. In this study, we evaluated the...

TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study

Lung adenocarcinoma with negative TTF-1 expression is believed to be a poor prognostic factor for certain systemic treatments. Nevertheless, the impact of TTF-1 expression on...

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC

Durvalumab maintenance therapy after definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III NSCLC. Although severe treatment-related...

Multicenter, retrospective study to evaluate necitumumab plus cisplatin/gemcitabine after immune checkpoint inhibitors in advanced squamous cell lung cancer in Japan: The NINJA study

Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of...

First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan

Pembrolizumab became available in Japan in February 2017 for first-line monotherapy of unresectable advanced and metastatic NSCLC with programmed death-ligand 1 (PD-L1) tumor...

Pre-Order Your Copy of the 50th Anniversary Book!

We are getting ready to celebrate IASLC's 50th anniversary in 2024! Don't miss out, pre-order your copy of the book today.

Pre-Order Yours Today!